Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州查爾斯敦，2024年4月3日（GLOBE NEWSWIRE）——開發神經肌肉和心臟疾病精準基因藥物的生命科學公司Solid Biosciences Inc.（納斯達克股票代碼：SLDB）今天宣佈向兩名新僱員發放激勵獎勵。這些補助金是根據公司2024年的激勵性股票激勵計劃發放的，是根據納斯達克上市規則5635（c）（4），作爲激勵每位員工接受公司工作的激勵材料。
The Company granted restricted stock unit awards with respect to an aggregate of 17,090 shares of its common stock to two new employees. The restricted stock unit awards vest in four equal installments on each one-year anniversary of the applicable employee's start date until the fourth anniversary of the applicable employee's start date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through the applicable vesting dates.
公司向兩名新員工發放了總共17,090股普通股的限制性股票單位獎勵。限制性股票單位獎勵在適用員工入職日期的每一年週年之內分四次等額分期發放，直至適用員工入職日期四週年。股權獎勵的歸屬取決於相關員工在適用的歸屬日期之前繼續在公司任職。
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
關於固體生物科學
Solid Biosciences是一家生命科學公司，專注於推進候選基因療法產品組合，包括用於治療杜興氏肌營養不良症（杜興納）的 SGT-003、用於治療兒茶酚胺能多態性心動過速（CPVT）的 SGT-501、用於治療 BAG3 介導的擴張型心肌病的 AVB-401 以及用於治療致命心臟病的其他資產。Solid 正在推進其針對罕見神經肌肉和心臟疾病的多元化產品線，彙集了科學、技術、疾病管理和護理領域的專家。Solid 以患者爲中心，由直接受影響的人創立，其使命是改善患有這些毀滅性疾病的患者的日常生活。欲了解更多信息，請訪問 www.solidbo.com。
Solid Biosciences Investor Contact:
investors@solidbio.com
固體生物科學投資者聯繫方式：
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒體聯繫人：
格倫·西爾弗
FINN 合作伙伴
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
資料來源：固態生物科學公司
譯文內容由第三人軟體翻譯。